Inhibiting USP14 lowers the IDO1 protein level, enhances the CD8 + T cells infiltration, reverses immune tolerance, as well as makes CRC tumor cells more sensitive to the anti-PD-1 therapy (Fig. 3B) [127]. Here, USP14 is linked to neoplasm.